The BLA also requests BAT2506 be declared interchangeable with Simponi. Bio-Thera and Intas entered into a license and commercialization agreement for BAT2506 in February 2025.

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the U.S. Food and Drug ...

The BLA also requests BAT2506 be declared interchangeable with Simponi. Bio-Thera and Intas entered into a license and commercialization agreement for BAT2506 in February 2025.

The BLA also requests BAT2506 be declared interchangeable with Simponi. Bio-Thera and Intas entered into a license and commercialization agreement for BAT2506 in February 2025.

BBC boss Tim Davie faces calls to quit over Glastonbury antisemitic chant coverage Outrage grows after broadcast of vile 'death to Israelis' outburst ...

The best shoes for Peloton and home exercise bikes are tried and tested by our in-house Tom's Guide fitness team, including models by Peloton, Rapha and more.

An intramuscular injection is a technique used to deliver a medication deep into the muscles. This allows the medication to be absorbed quickly. Learn more.

Explore the rise and market race of anti-IL23p19 therapies in Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis (UC). Stay informed on the latest advancements and treatment options.

The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for BAT2506, a proposed biosimilar to Simponi (golimumab). The FDA goal date set under the Biosimilar ...

GUANGZHOU, China I July 16, 2025 I Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced ...

Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to arthritis or other inflammatory conditions. Options range from OTC pain relievers ...